Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SG301 SC in pediatric frequently relapsing or steroid-dependent nephrotic syndrome
ChiCTR2500104540Phase 2Not yet recruiting
- Sponsor
- Children's Hospital, Zhejiang University School of Medicine
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SG301 in nephrosis, sponsored by Children's Hospital, Zhejiang University School of Medicine. Primary endpoints: Adverse events and serious adverse events during treatment, Recurrence-free survival at 6 months and 1 more. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
SG301
03
Conditions
nephrosis
Beyond the preview
Go deeper on ChiCTR2500104540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500104540.